AzTrials
AzTrials

Psychotic DisordersDEMETERNCT06045897

EEG Microstates Across At-Risk Mental States

A study testing EEG 64 channels, Polysomnography 19 electrodes and Light hypnosis in people with Psychotic Disorders and Autism Spectrum Disorder, run by Centre Hospitalier St Anne at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6). Read more about this study

Who is it for?
Ages 15 to 30 yearsHealthy volunteers can take part
What is being tested?
EEG 64 channels, Polysomnography 19 electrodes and Light hypnosis
Could I receive a placebo?
No, everyone receives an active treatment
How many people
126 participants
Where
1 siteFrance
Study dates
30 May 2023to 30 Jul 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 30 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • age between 15 and 30 years
  • subjects meeting CAARMS criteria for stage Ia or Ib mental states at risk (for stage Ia, mild or nonspecific symptoms of psychosis or severe mood disorder, and mild functional impairment; for stage Ib, moderate symptoms below intervention threshold and moderate functional impairment)
  • subjects meeting any DSM-5 criteria associated with a first onset of psychotic symptoms (first episode psychosis)
  • subjects satisfying DSM-5 criteria for depressive disorder
  • subjects meeting DSM-5 criteria for autism spectrum disorder
  • healthy control subjects recruited from the general population

Who cannot join

  • suicidal risk
  • severe or non-stabilized somatic and neurological disorders
  • epilepsy
  • head trauma
  • IQ below 70
  • for healthy control subjects, a family history of psychosis is an exclusion criterion
Show all 9Show fewer
  • bipolar disorder
  • obsessive-compulsive disorder
  • substance use disorder, except for cannabis, tolerated up to 5 joints/day.

Trial locations and contacts

1 site in 1 country.

Anton Iftimovici, MD, PhD contact

0033(0)145658179

anton.iftimovici@ghu-paris.fr

Valeria Lucarini, MD, MS contact

0033(0)145658179

valeria.lucarini@ghu-paris.fr

France1 site, 1 recruiting
  • Centre de Recherche Clinique, Hôpital Sainte-Anne, GHU Paris Psychiatrie et Neurosciences

    Paris, 75014

    Bénédicte Coutard, 0033(0)145656250, b.coutard@ghu-paris.fr

    Anton Iftimovici, MD, PhD

    Recruiting

Other trials in France

About this study

Official title: Determination of EEG Microstates Associated With Mental Disorders in At-Risk States (Détermination Des Microétats EEG associés Aux Troubles Psychiques Dans Les États à Risque - DEMETER)

The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6). The main questions it aims to answer are:

  • are EEG microstate anomalies associated with diagnosis, clinical and functional prognosis, both in resting conditions and during sleep ?
  • are EEG microstates anomalies associated with differences in sensorimotor integration, prosodic and conversational, interoceptive, and narrative self ?
  • an ancillary study will be to see whether in healthy controls EEG microstate properties vary under light hypnosis conditions.
Read more

Participants will:

  • undergo deep phenotyping based on psychopathology and neuropsychological assessments
  • undergo a high-resolution EEG (64 electrodes) with a resting period and a sensorimotor task; and healthy controls will have a light hypnosis period.
  • undergo a recording of the characteristics of their voice (tone, prosody)
  • undergo a one-night polysomnography
  • undergo MRI and biological sampling for multi-omic analyses
  • undergo a virtual reality experience
Read the detailed description
  • Aim of the study: EEG microstates translate the resting-state temporal dynamics of neuronal networks throughout the brain. Here, the investigators aim to see whether EEG microstate anomalies could constitute markers of psychiatric disorders.
  • Methods: six groups of 21 participants each will be included. There will be five groups of participants with psychiatric disorders (at-risk-mental state - ARMS, first-episode psychosis - FEP, schizophrenia - SCZ, major depressive disorder - MDD, and autism spectrum disorders - ASD) and one group of healthy controls. Our main objective is to test differences in means between the groups, at rest and during sleep, for each of the variables characterizing each of the microstates (duration, frequency, occupation time) as well as, secondarily, EEG measures of connectivity (somatosensory evoked potentials), cortical excitability (alpha-band power), and prosodic and conversational linguistic measures.
  • Regarding the microstates measures: a five minute eyes-closed resting-state EEG with 64 channels will be recorded (as part of the larger task including the sensorimotor task described below). A minimal preprocessing will be done with the MNE EEG software on Python, which includes a bandpass filter between 0.5 and 40 Hz, rereferencing to the mean, and visual and automatic correction for artifacts. Each recording will be visually reanalyzed by clinical neurophysiologists to ensure it is indeed an alpha-dominant, resting rhythm without any residual artifact. Microstate analysis will be done using the Pycrostates package. Global field power (GFP) will be determined for each participant. Only EEG topographies at GFP peaks will be retained to determine microstates' topographies, through a modified K-means clustering. For each subject the same number of GFP peaks will be extracted and concatenated into a single data set for clustering. A combined score will be used to compute the optimal number of clusters. The resulting clusters will be backfitted to each individual maps. Temporal smoothing will be used to ensure that periods of inter-peak noise, of low GFP, did not interrupt the sequences of quasi-stable segments. For each subject, three parameters will be computed for each microstate class: frequency of occurrence ("occurrence"), temporal coverage ("coverage") and mean duration. Occurrence is the average number of times a given microstate occurs per second. Coverage (in %) is the percentage of total analysis time spent in a given microstate. Mean duration (in ms) is the average time during which a given microstate was present in an uninterrupted manner (after temporal smoothing).
  • Regarding the linguistic measures: each participant undergoes a semi-structured interview with a trained experimenter. Both the participant and the interviewer wear head-set AKG-C544L condenser microphones, connected via AKG MPA VL phantom adaptors to a Zoom H4n Pro Handy recorder. Speech is digitally recorded at a sampling rating of 44000 Hz (16-bit). The distance between the mouth and the microphone is kept as constant as possible (2 cm) to assure consistent levels of vocal loudness. The interviews are done in a quiet room to limit environmental noise; the two interactants are placed as far as possible, to prevent crosstalk (i.e. speech of the interviewer caught by participant's microphone and vice versa). The .wav files obtained from the recordings are annotated using the Praat software and subsequently analysed with Praat and R. Prosodic features are extracted using the Prosogram tool (a set of Praat scripts, open-source) and a new modified version of scripts from the Prosogram tool. Turn-taking variables are extracted with new combined Praat and R scripts.
  • Regarding the sensorimotor intergration measures: the sensorimotor integration is investigated using a visuo-haptic task. On each trial, the participant, seated in front of a screen, has a visual instruction (a point to the right or left of the screen). The task consists of pressing one of the two buttons positioned on each side of the body with the index finger of the corresponding hand according to the visual instruction. A vibrotactile stimulator (small speakers wired to an Arduino electronic card modulated by an amplifier) is applied to the first dorsal interosseous muscle of both hands. 400 msec before the visual instruction, one of the two hands receives a tactile cue (vibration) on one hand for 100 msec. This cue is more or less reliable depending on the block. In some blocks, it is quite reliable, since 90% of the trials present the vibration and visual instruction congruently (indicating the same hand). Another condition is composed of only 50% of the congruent trials, and in this case, the tactile cue is not reliable. Two blocks with 70% congruent cases are carried out intermediately. Finally, a baseline block which does not contain any tactile cues is presented at the beginning and the end of the task. The order of the 90% and 50% blocks is randomized. The tactile and visual stimuli are generated with a MATLAB script. Each block consists of 100 trials, in total 500 trials. Electroencephalographic (EEG) data is recorded throughout the task, using a 64-channel EEG cap (from Biosemi) in order to record the electrical brain activity. The setup is coupled to an eyetracker, to control that the participant is fixating the cross at the center of the screen during each block.
  • Regarding the multidimensional self and episodic memory task (task design: Laboratoire Mémoire, Cerveau et Cognition): at baseline, participants will be submitted to self-reported questionnaires assessing their sense of minimal Self on 8 domains (Multidimensional Assessment of Interoceptive Awareness - Version 2) and sense of narrative Self on 5 domains (Tennessee Self Concept Scale - Short Form, Present). They will undergo a neuropsychological test assessing their visual episodic memory performance (Family Pictures from Wechsler Memory Scale-III). They will rate their current emotional state on a visual analogue scale on 4 domains (Mood Visual Analogue Scale). Following each of the two navigation sessions in virtual reality, which consist in a walk through a virtual city where participants encounter daily life events that aim to be incidentally encoded in episodic memory, associated with different levels of self-reference, participants will be submitted to self-reported questionnaires assessing their sense of embodiment on 4 domains (Embodiment Questionnaire), their sense of presence on 4 domains (Igroup Presence Questionnaire), and their cybersickness on 2 domains (Simulator Sickness Questionnaire). They will rate again their current emotional state on a visual analogue scale (Mood Visual Analogue Scale). Finally, participants will undergo two episodic memory tests: a free recall task and a recognition task. The free recall will be based on a verbal interview of 20 minutes, during which participants will be asked to recall all the events that they remember encountering in the virtual city. For each event, they will be asked to recall systematically and the most precisely possible: what was the event, where and when it happened during the navigation, in which of the two navigation it happened (source), who was the referent according to which the personal significance of the event was assessed, objective (perceptive) and subjective (phenomenological) details of the event, and if the event was vividly relived or felt merely familiar (Remember/Know procedure). The recognition test will be performed on a computer and programmed using the Python module Neuropsydia. All 32 encountered events mixed with 16 lures which were not encountered will be displayed successfully in a random order on a computer screen. For each event, several questions will be asked successfully and participants will click on what they consider the correct answer among several propositions: did they encounter the event (Yes/No), and if yes where it happened (among several possible localisations on a picture of the zone where the event occurred), when it happened (replacing the event in the chronological order with two other events), in which navigation (first or second navigation), and who was the referent (Me/Other). For each event, participants will also rate on scales ranging from 0 to 100: the degree of reliving or familiarity of the event (100 = Remember, 0 = Know), the perspective of the memory (100 = first-person perspective, 0 = third-person perspective), its vivacity, fidelity, emotional intensity, strength of associated bodily sensations, episodic self-reference, and semantic self-reference.

For all variables, the investigators will apply a repeated measures ANOVA, and use the following contrasts:

  1. "ARMS, FEP, SCZ, ASD, MDD" vs. "Healthy subjects" (microstates are tested as markers of general psychopathology);
  2. "ARMS, FEP, SCZ" vs "ASD, MDD" (microstates are tested as specific markers of psychosis; equivalently, the specificity of this signature for depression and ASD will be tested)
  3. "ARMS" vs. "FEP" vs. "SCZ" (microstates are tested as evolutionary markers);
  4. Finally, depending on the rate of transition to psychosis among UHRs, a comparison of "UHR-T" vs "UHR-NT" can be made (microstates are tested as predictive markers of psychosis All subjects will undergo a deep phenotyping including neuropsychology, psychopathology, neurological soft signs scales, as well as structural MRI, and genetic and epigenetic measures.
  • Hypothesis: imbalances in EEG microstates C and D are expected to be more pronounced across the spectrum of psychosis and in ASD compared to controls, MDD, and ARMS, and be associated with anomalies in somatosensory, interoceptive, and language characteristics.
Being tested
EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis, Biological sampling, Virtual reality
Keywords
electroencephalography, at risk mental state, ultra high risk, first episode psychosis, schizophrenia, autism spectrum disorder, EEG microstates, polysomnography, sensorimotor integration, prosody, hypnosis
Medical subject headings
Psychotic Disorders, Autism Spectrum Disorder, Depressive Disorder, Major, Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EEG 64 channelsDevice

    64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.

  • Polysomnography 19 electrodesDevice

    Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.

  • Light hypnosisBehavioural

    Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.

  • Biological samplingBiological

    Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.

  • Virtual realityBehavioural

    Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.

  • Voice recordingDevice

    A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.

Study groups in NCT06045897
Study groupRoleWhat they receive
Major depressive disorderExperimentalMajor depressive disorder as defined by DSM-5 classification
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Biological: Biological sampling; Device: Voice recording
Autism spectrum disorderExperimentalAutism spectrum disorder as defined by DSM-5 classification
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Biological: Biological sampling; Device: Voice recording
At risk mental stateExperimentalAt risk mental state as defined in the CAARMS
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Biological: Biological sampling; Behavioral: Virtual reality; Device: Voice recording
First episode psychosisExperimentalAny DSM-5 category associated with psychotic symptoms
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Biological: Biological sampling; Behavioral: Virtual reality; Device: Voice recording
SchizophreniaExperimentalSchizophrenia as defined by DSM-5 classification
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Biological: Biological sampling; Device: Voice recording
Healthy controlsExperimentalHealthy controls with no history of neurodevelopmental disorder or psychotic disorder in a first degree relative
Receives: Device: EEG 64 channels; Device: Polysomnography 19 electrodes; Behavioral: Light hypnosis; Biological: Biological sampling; Behavioral: Virtual reality; Device: Voice recording

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurrence of EEG microstates

    Average number of times a given microstate occurs per second.

    Measured: Three years

  2. Coverage of EEG microstates

    Percentage of total analysis time spent in a given microstate.

    Measured: Three years

  3. Mean duration of EEG microstates

    Average time during which a given microstate was present in an uninterrupted manner (after temporal smoothing).

    Measured: Three years

Secondary outcomes (67)
  1. Attention modulation

    Measurement of alpha band power (in Hz)

    Measured: Three years

  2. Cortical excitability and inhibition

    Measurement of mu and theta bands (in Hz)

    Measured: Three years

  3. Integration of sensory information: amplitudes

    Measurement of amplitudes (in µV) of somatosensory evoked potentials

    Measured: Three years

  4. Integration of sensory information: latencies

    Measurement of latencies (in msec) of somatosensory evoked potentials

    Measured: Three years

  5. Reaction time

    The adaptation of the reaction time (in msec) to the button press according to the probabilistic context of congruency is examined.

    Measured: Three years

  6. Speech rate

    Measurement of number of syllables/sec in the recording of the subjects

    Measured: Three years

  7. Fundamental frequency

    Measurement of the fundamental frequency (in Hz)

    Measured: Three years

  8. Pitch mean

    Measurement of the pitch mean (in semi-tones)

    Measured: Three years

  9. Pitch range

    Measurement of the pitch range (in semi-tones)

    Measured: Three years

  10. Pitch gliss

    Measurement of the proportion of syllables with large pitch movement (in percents)

    Measured: Three years

  11. Pitch rises

    Measurement of the proportion of syllables with pitch rise (in percents)

    Measured: Three years

  12. Pitch falls

    Measurement of the proportion of syllables with pitch fall (in percents)

    Measured: Three years

  13. Nuclei duration

    Sum of durations for syllable nuclei for the speaker (in seconds)

    Measured: Three years

  14. Internuclei Duration

    Sum of durations between successive nuclei for the speaker (in seconds)

    Measured: Three years

  15. Intrasyllabic Trajectory

    Pitch trajectory (sum of absolute intervals) within syllabic nuclei, divided by duration (in semitones per second)

    Measured: Three years

  16. Intersyllabic Trajectory

    Pitch trajectory (sum of absolute intervals) between syllabic nuclei (except pauses or speaker turns), divided by duration (in semitones per second)

    Measured: Three years

  17. Percentage of turns interviewer

    Interviewer's total number of turns divided by the total number of turns of the dialogue (in percents)

    Measured: Three years

  18. Percentage of turns participant

    Participant's total number of turns divided by the total number of turns of the dialogue (in percents)

    Measured: Three years

  19. Interviewer's Floor Occupation

    Portion of time where only the interviewer is speaking (in percents)

    Measured: Three years

  20. Participant's Floor Occupation

    Portion of time where only the participant is speaking (in percents)

    Measured: Three years

  21. Overlap

    Portion of time where both interactants are speaking (in percents)

    Measured: Three years

  22. Mutual silence

    Portion of time where both interactants are silent (in percents)

    Measured: Three years

  23. Between-Overlap

    Turn transition composed of overlapping speech from both interlocutors (in percents)

    Measured: Three years

  24. Gap

    Silent interval between turn transitions (in percents)

    Measured: Three years

  25. Within-Overlap

    Passages of overlapping speech not followed by a change of speaker (in percents)

    Measured: Three years

  26. Floor Transfer Offset

    Measures of gaps (positive values) and overlaps (negative values) in milliseconds

    Measured: Three years

  27. Interviewer's Speaking Turn Duration

    Average duration of interviewer's speaking turns in milliseconds

    Measured: Three years

  28. Interviewer's Silent Turn Duration

    Average duration of interviewer's pauses in milliseconds

    Measured: Three years

  29. Participant's Speaking Turn Duration

    Average duration of the participant's speaking turns in milliseconds

    Measured: Three years

  30. Participant's Silent Turn Duration

    Average duration of the participant's pauses in milliseconds

    Measured: Three years

  31. Minimal self

    Measure on the Multidimensional Assessment of Interoceptive Awareness - Version 2; Min = 0, max =185; Higher score is a better outcome

    Measured: Three years

  32. Narrative self

    Measure on the Tennessee Self Concept Scale - Short Form, Present; Min = 21, max = 105; Higher score is a better outcome

    Measured: Three years

  33. Visual episodic memory performance

    Measure on the Family Pictures from Wechsler Memory Scale-III (standardized score)

    Measured: Three years

  34. Current emotional state before the task

    Measure on the Mood Visual Analogue Scale; Min = 0, max = 100; Higher score is a better outcome

    Measured: Three years

  35. Embodiment

    Measure on the Embodiment Questionnaire; Min = -3, max = 3; Higher score is a better outcome

    Measured: Three years

  36. Presence

    Measure on the Igroup Presence Questionnaire; Min = -42, max = 42; Higher score is a better outcome

    Measured: Three years

  37. Cybersickness

    Measure on the Simulator Sickness Questionnaire; Min = 0, max = 48; Higher score is a worse outcome

    Measured: Three years

  38. Current emotional state after the task

    Measure on the Mood Visual Analogue Scale; Min = 0, max = 100; Higher score is a better outcome

    Measured: Three years

  39. Recognition task: "What" 1

    Proportion of hits (number of recognised events divided by total number of events) (in percents)

    Measured: Three years

  40. Recognition task: "What" 2

    Proportion of false alarms (number of falsely recognised lures divided by total number of lures) (in percents)

    Measured: Three years

  41. Recognition task: "What" 3

    Hit mean reaction time (in seconds)

    Measured: Three years

  42. Recognition task: "What" 4

    False alarm mean reaction time (in seconds)

    Measured: Three years

  43. Recognition task: "When"

    Proportion of correct "When" answers (number of correct "When" answers divided by number of hits) (in percents)

    Measured: Three years

  44. Recognition task: "Where"

    Proportion of correct "Where" answers (in percents)

    Measured: Three years

  45. Recognition task: "Source"

    Proportion of correct "Source" answers (in percents)

    Measured: Three years

  46. Recognition task: "Binding What-When-Where"

    Mean of (What + When + Where) (in percents)

    Measured: Three years

  47. Recognition task: "Binding What-When-Where-Source"

    Mean of (What + When + Where + Source) (in percents)

    Measured: Three years

  48. Recognition task: "Referent"

    Proportion of correct "Referent" answers (in percents)

    Measured: Three years

  49. Recognition task: "Remember/Know"

    Mean (a score between 0 and 100)

    Measured: Three years

  50. Recognition task: "Perspective"

    Mean (a score between 0 and 100)

    Measured: Three years

  51. Recognition task: "Vivacity"

    Mean (a score between 0 and 100)

    Measured: Three years

  52. Recognition task: "Fidelity"

    Mean (a score between 0 and 100)

    Measured: Three years

  53. Recognition task: "Emotional intensity"

    Mean (a score between 0 and 100)

    Measured: Three years

  54. Recognition task: "Strength of associated bodily sensations"

    Mean (a score between 0 and 100)

    Measured: Three years

  55. Recognition task: "Episodic self-reference"

    Mean (a score between 0 and 100)

    Measured: Three years

  56. Recognition task: "Semantic self-reference"

    Mean (a score between 0 and 100)

    Measured: Three years

  57. Free recall: "What"

    Proportion of recalled events (in percents)

    Measured: Three years

  58. Free recall: "When"

    Proportion of correct "When" answers (in percents)

    Measured: Three years

  59. Free recall: "Where"

    Proportion of correct "Where" answers (in percents)

    Measured: Three years

  60. Free recall: "Source"

    Proportion of correct "Source" answers (in percents)

    Measured: Three years

  61. Free recall: "Binding What-When-Where"

    Mean of (What + When + Where) (in percents)

    Measured: Three years

  62. Free recall: "Binding What-When-Where-Source"

    Mean of (What + When + Where + Source) (in percents)

    Measured: Three years

  63. Free recall: "Referent"

    Proportion of correct "Referent" answers (in percents)

    Measured: Three years

  64. Free recall: "Objective details"

    Mean number of objective details

    Measured: Three years

  65. Free recall: "Subjective details"

    Mean number of subjective details

    Measured: Three years

  66. Free recall: "Remember/Know" 1

    Proportion of "Remember" answers (in percents)

    Measured: Three years

  67. Free recall: "Remember/Know" 2

    Proportion of "Know" answers (in percents)

    Measured: Three years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2023
  2. Study start30 May 2023
  3. Primary completion30 Jul 2026 (estimated)
  4. Study completion30 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
126 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06045897
Sponsor's protocol ID
2021-A01919-32
Acronym
DEMETER
Status last verified
Sep 2023
First submitted
12 Jul 2021
Last updated
21 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Iftimovici A, Marchi A, Ferat V, Pruvost-Robieux E, Guinard E, Morin V, Elandaloussi Y, D'Halluin A, Krebs MO, Chaumette B, Gavaret M. Electroencephalography microstates imbalance across the spectrum of early psychosis, autism, and mood disorders. Eur Psychiatry. 2023 May 29;66(1):e41. doi: 10.1192/j.eurpsy.2023.2414.

    PubMed 37246142
  • Gavaret M, Iftimovici A, Pruvost-Robieux E. EEG: Current relevance and promising quantitative analyses. Rev Neurol (Paris). 2023 Apr;179(4):352-360. doi: 10.1016/j.neurol.2022.12.008. Epub 2023 Mar 10.

    PubMed 36907708
  • Lucarini V, Alouit A, Yeh D, Le Coq J, Savatte R, Charre M, Louveau C, Houamri MB, Penaud S, Gaston-Bellegarde A, Rio S, Drouet L, Elbaz M, Becchio J, Pourchet S, Pruvost-Robieux E, Marchi A, Moyal M, Lefebvre A, Chaumette B, Grice M, Lindberg PG, Dupin L, Piolino P, Lemogne C, Leger D, Gavaret M, Krebs MO, Iftimovici A. Neurophysiological explorations across the spectrum of psychosis, autism, and depression, during wakefulness and sleep: protocol of a prospective case-control transdiagnostic multimodal study (DEMETER). BMC Psychiatry. 2023 Nov 21;23(1):860. doi: 10.1186/s12888-023-05347-x.

    PubMed 37990173

Questions about this trial

What is this clinical trial studying?

A study testing EEG 64 channels, Polysomnography 19 electrodes and Light hypnosis in people with Psychotic Disorders and Autism Spectrum Disorder, run by Centre Hospitalier St Anne at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anton Iftimovici, MD, PhD (0033(0)145658179, anton.iftimovici@ghu-paris.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurrence of EEG microstates (time frame: Three years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06045897, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in